公开(公告)号：WO2022174035A2

公开(公告)日：2022-08-18

申请号：PCT/US2022/016119

申请日：2022-02-11

Applicant: SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE

Inventor： KONING, Ryan ,  JOHNSON, Adam ,  SAXBY, Chris ,  JENSEN, Michael C. ,  BLUMENTHAL, Ian ,  REID, Aquene

IPC: C07K14/435 ,  A61K38/16 ,  C07K14/705 ,  A61K35/12 ,  A61K38/17 ,  A61K2039/5156 ,  A61K39/001104 ,  A61K39/001112 ,  A61K41/00 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/721 ,  C07K2319/03

Abstract: Activity-inducible fusion proteins whose activity is post-translationally regulated utilizing a hsp90 binding domain and a drug molecule are described. In the absence of the drug molecule, the activity-inducible fusion proteins are inactivated but can be activated by a relevant physiological parameter in the presence of the drug molecule. Examples of the activity-inducible fusion proteins include chimeric antigen receptors (CAR) wherein the relevant physiological parameter is antigen binding.

公开(公告)号：WO2022026577A1

公开(公告)日：2022-02-03

申请号：PCT/US2021/043499

申请日：2021-07-28

Applicant: NANTBIO, INC.

Inventor： GARBÁN, Hermes

IPC: C07K14/725 ,  C07K14/705 ,  C12N15/62 ,  C12N15/85 ,  A61K39/00 ,  A61K2039/5156 ,  A61K35/17 ,  A61K39/001103 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001112 ,  A61K39/001129 ,  C07K14/7051 ,  C07K14/70521 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

Abstract: Compositions and methods for eradicating tumor cells using novel compositions are contemplated. In one aspect, a pharmaceutical composition comprising a CAR scaffold and an antigen binding domain in a single chimeric species is provided. In some aspects, the CAR scaffold may comprise a CD28 costimulatory signaling region and a CD3ζ activation domain or a complete CD3ζ activation domain. In some aspects, the CAR scaffold may be codon-optimized for improved expression in mammalian cell lines and/or for improved function upon transfection into natural killer (NK) or other immune cells. In further aspects, the antigen binding domain may comprise a VL and VH domain linked by a spacer and may be codon optimized. A CD64 leader sequence may be attached to the antigen binding domain, e.g., at the N-terminus of the antigen binding domain.

公开(公告)号：WO2022094391A2

公开(公告)日：2022-05-05

申请号：PCT/US2021/057543

申请日：2021-11-01

Applicant: NEUVOGEN, INC.

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd Merrill ,  HUNDT, Matthias ,  LEWIS, Amritha Balakrishnan ,  MOHLER, Kendall M. ,  SHAWLER, Daniel Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/575 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing breast cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to driver mutations. Also provided herein are methods of making and preparing the breast cancer vaccine compositions and methods of use thereof.

公开(公告)号：WO2022094386A1

公开(公告)日：2022-05-05

申请号：PCT/US2021/057536

申请日：2021-11-01

Applicant: NEUVOGEN, INC. [US]/[US]

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd, Merrill ,  HUNTDT, Matthias ,  LEWIS, Amritha, Balakrishnan ,  MOHLER, Kendall, M. ,  SHAWLER, Daniel, Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/575 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (I) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (II) express or increase expression of one or more immunostimulatory factors by the cells, and/or (ill) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to acquired tyrosine kinase inhibitor (TKI) resistance mutations, EGFR activating mutations, and/or (v) express modified ALK intracellular domain(s), and/or express one or more driver mutations. Also provided herein are methods of making and preparing the vaccine compositions and methods of use thereof.

公开(公告)号：WO2021247525A1

公开(公告)日：2021-12-09

申请号：PCT/US2021/035184

申请日：2021-06-01

Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC.

Inventor： DAVILA, Marco L.

IPC: C07K16/28 ,  C07K16/30 ,  C12N5/00 ,  A61K2039/5156 ,  A61K39/001104 ,  A61K39/00117 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/2863 ,  C07K16/3092 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/03 ,  C07K2319/33

Abstract: Bi-specific CAR-T cells are disclosed for treating NSCLCs. The disclosed CAR-T cells contain CAR polypeptides that can bind EGFR/MUC1-expressing cells. Therefore, also disclosed is an immune effector cell genetically modified to express an anti-EGFR CAR binding agent and an anti-MUC1 binding agent. Also disclosed are methods of providing an anti-tumor immunity in a subject with a EGFR and MUC1-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

公开(公告)号：WO2021242798A1

公开(公告)日：2021-12-02

申请号：PCT/US2021/034137

申请日：2021-05-26

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： LI, Ning

IPC: A61K35/66 ,  A61P31/00 ,  A61P37/02 ,  A61K2039/523 ,  A61K2039/6006 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/001104 ,  A61K39/215 ,  C07K14/005 ,  C07K14/71 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/569 ,  C07K2319/00 ,  C07K2319/035 ,  C12N1/20 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12R2001/19

Abstract: Recombinant microorganisms, pharmaceutical compositions thereof, and methods of protein display on the cell surface of the microorganisms are disclosed.

公开(公告)号：WO2022247972A2

公开(公告)日：2022-12-01

申请号：PCT/CU2022/050004

申请日：2022-05-19

Applicant: CENTRO DE INMUNOLOGIA MOLECULAR ,  INNOVATIVE IMMUNOTHERAPY ALLIANCECE S.A.

Inventor： CROMBET RAMOS, Tania ,  MESA PARDILLO, Circe ,  LEÓN MONZÓN, Kalet ,  MAZORRA HERRERA, Zaima ,  SAAVEDRA HERNÁNDEZ, Danay ,  LORENZO-LUACES ÁLVAREZ, Patricia ,  DY, Grace ,  REID, Mary ,  EVANS, Rachel ,  MUHITCH, Jason ,  LEE, Kelvin ,  HUTSON, Alan ,  JOHNSON, Candace

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/575 ,  A61K2300/00 ,  A61K39/001104 ,  C07K16/2818 ,  C07K16/2827 ,  G01N2800/52

Abstract: La presente invención se relaciona con las ramas de la Biotecnología y la Medicina. Describe el uso de composiciones terapéuticas que comprenden un compuesto que bloquea al factor de crecimiento epidérmico y un anticuerpo que bloquea la vía de señalización PD-1/PD-1 ligando en el tratamiento de tumores de origen epitelial, particularmente en aquellos que expresan la forma nativa de la proteína KRAS humana. En los pacientes con cáncer de origen epitelial que expresan KRAS nativo tratados con dichas composiciones terapéuticas, se observó un aumento de la supervivencia de los mismos.

公开(公告)号：WO2022094388A2

公开(公告)日：2022-05-05

申请号：PCT/US2021/057539

申请日：2021-11-01

Applicant: NEUVOGEN, INC.

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd, Merrill ,  HUNDT, Matthias ,  LEWIS, Amritha, Balakrishnan ,  MOHLER, Kendall, M. ,  SHAWLER, Daniel, Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing colorectal cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (I) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (II) express or increase expression of one or more immunostimulatory factors by the cells, and/or (ill) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to driver mutations. Also provided herein are methods of making and preparing the colorectal cancer vaccine compositions and methods of use thereof.

公开(公告)号：WO2022040586A2

公开(公告)日：2022-02-24

申请号：PCT/US2021/046994

申请日：2021-08-20

Applicant: NOVARTIS AG

Inventor： KOSHY, Sandeep Tharian ,  DRANOFF, Glenn ,  BROGGI, Maria Anna Sofia ,  BRIDGEMAN, Chris ,  CANHAM, Stephen Michael ,  MELLES, Yoel ,  CEBE, Regis ,  GRANDA, Brian Walter ,  TREANOR, Louise Mary ,  JAYASHANKAR, Shyamali ,  YANG, Jennifer ,  RAYO, Amy ,  PRICE, Andrew Patrick ,  SKEGRO, Darko ,  GUYOT, Justine ,  APSUNDE, Tushar Dattu ,  LEE, Cameron Chuck-munn ,  BARDROFF, Michael ,  MILLER, Sandra

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/49 ,  C07K14/725 ,  A61K48/00 ,  A61K38/18 ,  A61K47/59 ,  A61K9/00 ,  A61K47/69 ,  A61K47/61 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  A61K38/1866 ,  A61K39/001104 ,  A61K39/001112 ,  A61K47/6901 ,  A61K47/6903 ,  A61K47/6923 ,  A61K47/6929 ,  A61K48/0008 ,  A61K9/0019 ,  C07K14/7051 ,  C07K2319/03

Abstract: Aspects of this disclosure relate generally to the use of biomaterials for the in vivo generation of CAR expressing cells. In some embodiments, the biomaterials comprise one or more of a cell recruitment composition, a viral vector, and/or a cell activation agent.

公开(公告)号：WO2021147121A1

公开(公告)日：2021-07-29

申请号：PCT/CN2020/074252

申请日：2020-02-04

Applicant: 中国科学院动物研究所

Inventor： 赵同标 ,  靳利远 ,  朱颖婕 ,  曹磊 ,  曹佳妮 ,  李晓燕

IPC: C12N5/10 ,  C12N15/12 ,  C12N15/63 ,  C12N15/62 ,  A61K35/17 ,  A61P35/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001142 ,  C07K14/523 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2863 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  C12N15/86 ,  C12N2510/00 ,  C12N2740/15043 ,  C12N2800/107 ,  C12N5/0636 ,  C12N5/0645 ,  C12N5/0646

Abstract: 提供了基因修饰的免疫细胞，该免疫细胞表达嵌合抗原受体并过表达趋化因子受体CCR6，增强了免疫细胞在实体肿瘤处的归巢和聚集以及实体瘤浸润，进而增强了免疫细胞对于实体肿瘤的治疗效果。还提供了修饰免疫细胞的方法和免疫细胞在制备治疗肿瘤的药物中的应用。